TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07816237: A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhi

Sponsor: Bisirna Therapeutics (Suzhou) Co., Ltd. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 70 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,485,920

Rescue Site Savings

+$5,610,136

Unlock Full NCT07816237 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07816237 Rescue Dossier →